Strata Oncology partnered with UW Health to integrated its next generation sequencing tumor profiling test into the health system's Epic EHR. Being able to order the test and see its results from within the EHR will help UW clinicians more efficiently leverage genomic findings into their precision oncology treatment plans.
The future of precision medicine will come only as quickly as doctors can pick out clinically useful information from the genetic data being gathered on their patients.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Lower costs for capital and sequencing, a friendlier regulatory and reimbursement environment and growth in precision medicine are among driving factors.
The company plans to bring NGS to health systems lacking the ability to perform it internally.
Strata Oncology might be the missing piece in personalized cancer care. The company plans to sequence 100,000 tumor samples for free, matching eligible patients with ongoing pharma trials. Patients, pharma and Strata all win -- if they can pull it off.